The effect of Pentoxifylline on C reactive protein level and dialysis adequacy
Phase 3
- Conditions
- Condition 1: esrd. Condition 2: Ischemic Heart Disease.Chronic kidney Disease, stage 5Angina pectoris, Acute myocardial infarction, Subsequent myocardial infarction, Certain current complications following acute myocardial infarction, Other acute ischaemic heart diseases, Chronic ischaemic heart disease,120-125
- Registration Number
- IRCT2013120715695N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
acceptance of written consent; End Stage Renal Disease; more than 15year; BMI between 15 - 35
Exclusion criteria: pentoxifylline use before study; no acceptance of written consent; abnormal LFT; hyper sensitivity reaction to pentoxifylline; active infection; recent malignancy; depression;recent ICH; recent retinal hemorrhage; dialysis period under 3 months
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CRP. Timepoint: before and after receiving placebo or drug. Method of measurement: quantitative kit of CRP.
- Secondary Outcome Measures
Name Time Method Dialysis Adequacy. Timepoint: before and after dialysis and before and after receiving placebo or drug. Method of measurement: KT/V: K ( cc/min ) x time ( min ) / urea volume ( cc ).